Shorter Radiation After Prostate Surgery: NRG-GU003 Explained

Short answer: The phase 3 NRG-GU003 trial found that a 25-treatment radiation course after prostate removal was not worse than a 37-treatment course for patient-reported urinary and bowel symptoms at two years. The shorter course caused more bowel irritation near the end of treatment, but that difference resolved by six months.

Why is radiation used after prostatectomy?

After radical prostatectomy, a PSA that remains detectable or begins rising can indicate prostate cancer cells remain. Radiation to the prostate bed, sometimes with pelvic lymph-node treatment and hormone therapy, may be used to reduce the risk of further progression.

Modern practice often favors early salvage radiation when PSA evidence of recurrence appears rather than automatically treating everyone with adverse pathology immediately after surgery. The right timing depends on PSA, pathology, genomic information when available, imaging, recovery of urinary control, and other health factors.

What did NRG-GU003 test?

NRG-GU003 enrolled 296 people receiving post-prostatectomy radiotherapy. Participants were randomly assigned to:

• 62.5 Gy in 25 treatments over about five weeks, called hypofractionated post-prostatectomy radiotherapy; or
• 66.6 Gy in 37 treatments over about seven and a half weeks, called conventionally fractionated radiotherapy.

The primary question was whether the shorter schedule produced patient-reported urinary and bowel outcomes at two years that were not unacceptably worse.

What did patients report?

At the end of radiation, urinary symptom changes were not meaningfully different between groups. Bowel symptoms were worse with the 25-treatment schedule at treatment completion. By six months, the difference had resolved, and both groups had returned to baseline.

At 24 months, the shorter course met the trial's criteria for noninferiority for both urinary and bowel symptoms. Based on these results, the investigators described 25-treatment post-prostatectomy radiation as a new acceptable practice standard.

What about cancer recurrence?

At a median follow-up of roughly 2.1 years, the reported biochemical failure rates were 12% with 25 treatments and 8% with 37 treatments. The difference was not statistically significant.

That finding should be interpreted carefully. The study was designed primarily around patient-reported side effects, not to prove equal long-term cancer control. Prostate cancer can recur years later, so continued follow-up is valuable.

Shorter does not mean the same plan for everyone

The number of treatments is only one part of post-prostatectomy care. A plan may differ based on:

• PSA level and how quickly it is rising;
• surgical pathology, including margins and seminal-vesicle or lymph-node involvement;
• molecular imaging results;
• urinary recovery after surgery;
• whether pelvic lymph nodes should be included; and
• whether short- or longer-term hormone therapy may add benefit.

The 2024 AUA/ASTRO/SUO salvage guideline also emphasizes treating at a lower PSA when salvage radiation is appropriate. Waiting for a scan to become positive can sometimes miss the window when treatment has the best chance of success.

How might a shorter course help?

Reducing the course by 12 visits may mean:

• fewer trips to the treatment center;
• less time away from work or caregiving;
• lower transportation burden; and
• earlier completion of therapy.

Convenience should be weighed against the possibility of more short-term bowel irritation and against individual planning considerations.

Questions for your radiation oncologist

1. Is radiation recommended now, or should my PSA be observed?
2. Should I have PSMA PET or other molecular imaging?
3. Would my treatment include the prostate bed only or pelvic lymph nodes?
4. Does hormone therapy improve the expected benefit in my risk group?
5. Am I a good candidate for 25 treatments?
6. What can help manage bowel or urinary symptoms during treatment?

NRG-GU003 expands the choices available after prostate surgery. It does not replace personalized discussion about whether, when, and how salvage radiation should be delivered.

Questions patients often ask

Why might radiation be recommended after prostate surgery?

Radiation may be considered when PSA remains detectable or rises, or when pathology indicates a higher recurrence risk. The timing and use of hormone therapy depend on individual risk factors.

Is 25-treatment radiation now standard for everyone after prostatectomy?

NRG-GU003 supports it as an acceptable practice option, but anatomy, prior recovery, urinary function, target volumes, and clinician judgment still matter.

Did NRG-GU003 prove equal long-term cancer control?

Its primary endpoint was patient-reported urinary and bowel symptoms at two years. Biochemical failure was not significantly different at the reported follow-up, but longer oncologic follow-up remains important.

Sources and further reading

1. Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy. JAMA Oncology (2024).
2. Hypofractionated Post-Prostatectomy Radiotherapy: NRG-GU003 Trial Findings. NRG Oncology (2024).
3. AUA/ASTRO/SUO Guideline on Salvage Therapy for Prostate Cancer. American Society for Radiation Oncology (2024).